Category Archives: Market Access
Relating to Market Access sector of Life Sciences Industry
Commercial Eyes appoints Simon Higgins to head up new Commercialisation Services division
Commercial Eyes Pty. Ltd., one of Australia’s most successful health technology commercialisation companies, is pleased to announce the appointment of Simon Higgins to head up it’s new Commercialisation Services division. Simon joins Commercial Eyes with over 20 years’ experience in … Continue reading
PHARMAC prepares to take over the procurement of medical devices
Access to medical devices in New Zealand is changing The Therapeutic Products Bill will be published shortly, resulting in PHARMAC assuming responsibility for the procurement and funding of medical devices in addition to their current brief of medicines. This … Continue reading
PHARMAC issues a call for funding applications for medicines for rare disorders
Applications will be accepted until 5pm on the 5th of August 2019 and will be considered by the Rare Disorders Subcommittee at their meeting scheduled for the 24th of September 2019. Eligibility criteria: The medicine must have been approved … Continue reading
November 2018 PBAC Meeting Agenda
The November 2018 PBAC Meeting is scheduled to conclude today. Here, the Commercial Eyes Market Access team provides an analysis of the meeting agenda, including Sponsors with multiple submissions and the nature of requested listings by type. The … Continue reading
PBAC Meeting Outcomes – July 2018
The July 2018 PBAC Meeting Outcomes were published on 17th August 2018. With 64 outcomes in total, the Commercial Eyes Market Access team provides an overview of PBAC decision making, including additional analysis conducted on biosimilar and oncology submissions. … Continue reading
Public Submissions to the August 2018 PBAC Special Meeting – Part 2
In the second part of this two-part series (Read Part 1 about here) we bring you further insight into opinions from the public submissions to the August 2018 PBAC Special Meeting. Opinions from the Public Submissions Outcomes of the PBAC’s … Continue reading
Public Submissions to the August 2018 PBAC Special Meeting – Part 1
In the first of a two-part series, we provide insights into opinions from 28 public submissions to the August 2018 PBAC Special Meeting held on 17 August 2018 regarding considerations for PD-1 and PD-L1 checkpoint inhibitors for multiple cancer types … Continue reading
PBAC Special Meeting – August 2018
The August 2018 PBAC special meeting is scheduled for 17 August 2018 to consider options for listing PD-1 and PD-L1 checkpoint inhibitors for the treatment of multiple tumours (pan-tumour indications) on the PBS. Here, the Commercial Eyes Market Access team … Continue reading
Sponsors struggle with Ministerial discretion
The 2017 Medicines Australia Strategic Agreement with the Australian Government extended the existing five-year anniversary statutory price reduction (SPR) of 5% for F1 medicines and introduced new SPRs for drugs that have been listed for ten years and fifteen years … Continue reading
The long road to PBS listing for Orkambi
Orkambi (lumacaftor and ivacaftor), a treatment for cystic fibrosis (CF), will go before the PBAC for a fourth time at the upcoming July 2018 PBAC meeting. So far, the road to reimbursement has been filled with multiple rejections, a strong … Continue reading
